An interventional study of Zinc Sulfate and Placebo (Gelatin Tablet) in Human Papilloma Virus, sponsored by Spectrum Health Hospitals. Terminated at 1 site in United States. Open to female participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-22.
Sponsored by Spectrum Health Hospitals · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Atypical Squamous Cells of the Cervix with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Atypical Squamous Cells of the Cervix · United States.
Among the 13 studies in Atypical Squamous Cells of the Cervix with a site in United States, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2017, is one of 4 with no phase, and was the 11th registered.
28 studies on the registry are indexed under Atypical Squamous Cells of the Cervix; 4 are open to participants now.
Browse Atypical Squamous Cells of the Cervix studies →1 of the 13 studies in Atypical Squamous Cells of the Cervix with a site in United States is open now. Recruiting first, the newest first:
University of Alabama at Birmingham · Sites in United States
Ages 19+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Atypical Squamous Cells of the Cervix studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 21 Years to 65 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 112 across 21 interventional studies indexed under Atypical Squamous Cells of the Cervix.
Median enrollment 163 across the 12 interventional studies, 0 across the 1 observational. Of the 11 that completed or were terminated, 3 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
Spectrum Health Hospitals is the lead sponsor of 38 studies on the registry; none are open to participants now.
Spectrum Health Hospitals has 1 study filed under Atypical Squamous Cells of the Cervix — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Atypical Squamous Cells of the Cervix with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.
Upon enrollment eligible participants will be randomized and given a three-month supply of zinc sulfate or placebo to be taken as directed. They will have zinc serum lab testing at enrollment and upon study completion. Patients will also be asked to complete short questionnaires and to make study staff aware of any side effects they should experience.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zinc Sulfate 220mg twice daily for three months.
Dietary Supplement: Zinc Sulfate
Gelatin Placebo tablet twice daily for three months.
Other: Placebo (Gelatin Tablet)
Participant will take one 220mg tablet twice daily for three months.
Participant will take one tablet twice daily for three months.
Clearance rates of high risk HPV
Time frame: During 3 month treatment period
Progression versus Regression
Incidence of progression versus regression of cervical changes after treatment with oral zinc sulfate
Time frame: During 3 month treatment period
Side Effects
Rates of side effects from zinc sulfate
Time frame: After 3 month treatment period
Compliance Rates
Examine rates of patients finishing the 3-month course of zinc sulfate
Time frame: After 3 month treatment period
Parity
Examine the correlation of parity on HPV clearance
Time frame: After 3 month treatment period
Low Zinc Levels and Persistence
Examine potential correlation between low serum levels of zinc and persistence of HPV.
Time frame: After 3 month treatment period
Zinc Levels and Regression
Examine the relation between zinc levels before and after treatment and the relation to regression of HPV.
Time frame: After 3 month treatment period
Plan to share: No
Ran from Oct 2017 to primary completion in Jun 2019, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zinc Sulfate
Atypical Squamous Cells of the Cervix →
Spectrum Health Hospitals